ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.07
0.46%
US Tech 100
17,244.80
1.57%
S&P 500
5,099.96
1.02%
US Dollar vs CAD
1.36805
0.00%
Bitcoin
62,940.68
-1.25%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Qiagen NV (QGEN)

  7. Qiagen NV (QGEN) News

QGEN Qiagen NV

41.65
0.57 (1.39%)
Apr 26 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Qiagen NV QGEN NYSE Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.57 1.39% 41.65 18:56:36
Open Price Low Price High Price Close Price Previous Close
41.10 41.06 41.68 41.65 41.08
more quote information »

Recent News

Date Time Source Heading
4/24/202415:05GLOBEQIAGEN expands tuberculosis portfolio with new NGS Panel to..
4/09/202408:48GLOBEQIAGEN N.V. to release results for Q1 2024 and hold webcast
4/03/202415:05GLOBEQIAGEN strengthens its portfolio for cancer research,..
3/25/202415:05GLOBEQIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test..
3/18/202415:05GLOBEQIAGEN partners with International Panel Physicians..
3/11/202404:59GLOBEQIAGEN announces Form 20-F annual report filing for 2023..
2/27/202416:44GLOBEQIAGEN launches AI-derived biomedical knowledge base to..
2/27/202415:05GLOBEQIAGEN earns ACT Label for new eco-friendlier QIAwave..
2/15/202415:05GLOBEQIAGEN earns ACT Label for new eco-friendlier QIAwave..
2/08/202408:47EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2/06/202415:05GLOBEQIAGEN exceeds outlook for Q4 2023, led by 8% CER sales..
1/25/202409:00GLOBEQIAGEN announces partnership with Penn State University to..
1/23/202415:13EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
1/18/202415:05GLOBEQIAGEN announces details for completion of synthetic share..
1/11/202406:53GLOBEQIAGEN N.V. to release results for Q4 2023 and hold webcast
1/08/202408:59EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/08/202401:00GLOBEQIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use..
1/07/202412:07GLOBEQIAGEN announces plans to return approximately $300 million..
1/04/202415:05GLOBEQIAGEN to accelerate investments into QIAGEN Digital..
1/03/202401:00GLOBEQIAGEN expands business in Middle East with new regional..
11/30/202315:05GLOBEDNA Labs International solves significant cold cases with..
11/15/202315:05GLOBEQIAGEN launches TissueLyser III and RNeasy PowerMax Soil Pro..
11/09/202315:05GLOBEQIAGEN launches new QIAcuity digital PCR kits and updated..
11/06/202315:05GLOBEQIAGEN launches complete Sample to Insight workflow for..
11/02/202307:00PRNUSQIAGEN and Element Biosciences partner to offer complete..
10/30/202315:05GLOBEQIAGEN exceeds outlook for Q3 2023 with 5% CER sales growth..
10/26/202307:00GLOBEQIAGEN and Myriad Genetics partner to advance companion..
10/09/202310:14GLOBEQIAGEN N.V. to release results for Q3 2023 and hold webcast
10/04/202315:05GLOBEQIAGEN launches QuantiFERON-EBV RUO assay, facilitating..
9/28/202315:05GLOBEQIAGEN extends AI capabilities of its NGS interpretation..
9/27/202315:05GLOBEQIAGEN reports progress toward achieving Environmental,..
9/25/202315:05GLOBEQIAGEN enhances QIAwave portfolio with new eco-friendlier..
8/25/202315:48EDGAR2Form 144 - Report of proposed sale of securities
8/09/202320:55EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
8/09/202320:40EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
8/08/202315:05GLOBEQIAGEN delivers ahead of outlook for Q2 2023 with 9% CER..
8/07/202315:05GLOBEQIAGEN receives FDA approval for companion diagnostic to..
7/26/202315:15GLOBEBio-Rad and QIAGEN announce patent settlement and..
7/24/202306:41GLOBEQIAGEN N.V. to release results for Q2 2023 and hold webcast
7/18/202315:05GLOBEQIAGEN expands range of digital PCR kits and services for..
6/20/202315:05GLOBEFBI approves QIAGEN’s NGS-based ForenSeq MainstAY workflow..
6/16/202306:36GLOBEQIAGEN provides reminder on settlement mechanics of 2023 and..
6/15/202315:05GLOBEQIAGEN’s QuantiFERON-TB Gold Plus shows unique clinical..
6/13/202315:05GLOBEDanish National Genome Center selects QIAGEN for variant..
5/03/202315:05GLOBEQIAGEN exceeds outlook for Q1 2023 with 12% CER sales growth..
5/03/202304:30GLOBEQIAGEN welcomes U.S. Preventive Services Task Force..

Your Recent History

NYSE
QGEN
Qiagen NV
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved